Tech Company Financing Transactions
TenNor Therapeutics Funding Round
On 10/20/2024, TenNor Therapeutics raised $42 million in Series E funding from AMR Action Fund and private investors.
Transaction Overview
Company Name
Announced On
10/20/2024
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series E
Investors
Proceeds Purpose
The company intends to use the funds to support the development and to seek regulatory approval in China of rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
218 Xinghu St. Building B2 Room 711
Suzhou Industrial Park, 215123
China
Suzhou Industrial Park, 215123
China
Phone
Website
Email Address
Overview
TenNor Therapeutics was established in 2013 with operations in the historic city of Suzhou, China. The company specializes in research and development of new drugs for the treatment of digestive diseases caused by pathogens, including those resistant to available antibiotics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zhenkun Ma
Browse more venture capital transactions:
Prev: 10/20/2024: Nada venture capital transaction
Next: 10/20/2024: Biological Lattice Industries venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs